arrow
F

Francesco Autore

Fondazione Policlinico Universitario A. Gemelli IRCCS
H指数:18
被引数:1,057

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12

cBTKi治疗后无淋巴细胞增多是一种罕见现象,除主要表达于12号染色体三体性的CD49d阳性CLL外。

2026-04-070
OAAI
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian study.

伊布替尼或非BTK抑制剂疗法在复发华氏巨球蛋白血症中的应用?一项意大利多中心真实世界研究。

2026-02-160
OAAI
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study

家族性慢性淋巴细胞白血病比散发性形式的预后更差:一项意大利病例对照研究

2025-06-140
OAAI
Report of Consensus Panel 4 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphoma

第十二届华氏巨球蛋白血症国际研讨会共识专家组4关于非IgM淋巴浆细胞样淋巴瘤患者管理的报告

2025-04-080
PRE
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors

第十二届华氏巨球蛋白血症国际研讨会第五共识小组关于对共价BTK抑制剂不耐受或耐药患者管理的报告

2025-04-080
PREAI
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience
2025-01-140
OAAI
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience
2024-11-280
OAAI
First-line treatment of Waldenstrom's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies
2024-11-190
OAAI
Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

家族性与散发性慢性淋巴细胞白血病的比较:一项意大利多中心病例对照研究

BLOOD
IF23.1
2024-11-050
PRE
Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial
2024-10-230
PRE
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study
2024-02-112
PRE
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?
2023-08-311
OAAI
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study
2023-07-012
OA
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion
2023-01-090
OA